The FDA maintains the nation's food supply remains safe despite a sharp rise in cyclospora infections across multiple states this summer. Frank Yiannas, the acting deputy commissioner for food at the FDA, emphasized the agency's proactive response to tracking outbreaks, even as investigators struggle to pinpoint the contamination source.

Cyclospora cayetanensis, a parasite transmitted through contaminated food or water, has sickened hundreds of people in recent weeks. The infection causes severe gastrointestinal illness with symptoms including watery diarrhea, nausea, and abdominal cramping that can persist for weeks without proper treatment. The CDC and state health departments have linked cases to produce from multiple suppliers, complicating investigation efforts.

Yiannas acknowledged the difficulty in identifying patient zero. Cyclospora spreads through food consumed days or weeks before symptoms appear, making it challenging to trace items back to contaminated fields or processing facilities. The FDA has intensified collaboration with state agencies and produce distributors to narrow possibilities.

The agency's response includes increased inspections of high-risk facilities and enhanced testing protocols for imported produce, particularly from countries where cyclospora is endemic. FDA investigators work backward from patient interviews about food consumption, checking supply chains across multiple states and distribution networks.

For consumers, washing fresh produce under running water provides basic protection, though cyclospora oocysts resist standard sanitizers. Cooking food thoroughly kills the parasite. High-risk groups including immunocompromised individuals should consult healthcare providers about produce safety.

Antibiotic treatment with trimethoprim-sulfamethoxazole remains the standard remedy once diagnosed, though some patients require repeated courses. The CDC recommends healthcare providers consider cyclospora in patients with prolonged diarrhea during summer months, particularly in outbreak areas.

Yiannas's statement reflects the FDA's balancing